Tag: liquid biopsy industry share

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Liquid Biopsy Market Size And Revenue Forecast Through 2030

The market for liquid biopsy has experienced a significant expansion recently, projected to increase from $1.46 billion in 2025 to $1.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.3%. This notable growth during the past period is largely due to the inherent drawbacks of conventional tissue biopsy methods, a

The liquid biopsy market is poised for significant expansion, projected to reach $3.11 billion by 2030, driven by a robust compound annual growth rate (CAGR) of 16.2%. This forthcoming expansion is fueled by several key factors, including the escalating demand for personalized cancer therapies, a greater integration of liquid biopsy into standard cancer detection protocols, its broadened utility in tracking cancer recurrence, augmented expenditure on cancer diagnostics, and heightened understanding and acceptance among both medical professionals and patients. Within this projected timeframe, notable market developments are anticipated, such as the increased embrace of non-surgical cancer diagnostic methods, a heightened focus on leveraging liquid biopsy for the earliest possible identification of cancer, the growing need for continuous monitoring of therapeutic effectiveness, its wider application in tailored cancer treatment strategies, and its growing endorsement as a viable substitute for traditional tissue biopsies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

Liquid Biopsy Market Growth Drivers: What Factors Are Accelerating Expansion?

Enhanced governmental financial support directed towards improving cancer detection capabilities stands as a principal factor propelling the expansion of the liquid biopsy sector. This heightened public investment in cancer detection advancements stems largely from the escalating worldwide prevalence of cancer, the critical necessity for early identification to optimize therapeutic results, and a concentrated effort to curb medical expenditures through the implementation of pioneering diagnostic methodologies. Such governmental backing facilitates the liquid biopsy market by expediting research and development initiatives, providing crucial support for clinical studies, and encouraging the uptake of sophisticated, minimally invasive diagnostic tools that aid in earlier cancer identification and the formulation of tailored treatment plans. A pertinent example is the £118 million (equivalent to $150.38) earmarked by UK Research and Innovation, as reported in October 2024 on the UK government’s official platform, gov.UK, where £54 million originated from governmental sources and an additional £64 million (or $81.55) was contributed by collaborating entities, underscoring the significant financial impetus provided for advancements in cancer diagnostics.

Liquid Biopsy Market Segment Performance And Strategic Opportunities

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

Liquid Biopsy Market Trends: What Is Shaping Future Industry Growth?

Key players in the liquid biopsy sector are prioritizing the creation of cutting-edge technologies, like extensive circulating tumor DNA (ctDNA) genomic-profiling assays, with the goal of expediting noninvasive cancer characterization, facilitating quicker medical treatment choices, and expanding the availability of precision oncology, particularly in situations where tissue is scarce or inaccessible. These comprehensive ctDNA genomic-profiling assays work by examining fragments of cell-free DNA originating from tumors present in the bloodstream, thereby identifying somatic small variants, alterations in copy number, insertions or deletions, and indicators relevant to immuno-oncology such as bTMB and bMSI. This approach provides a more extensive understanding of the tumor without the drawbacks of invasive procedures, potential sampling biases, and extended processing times associated with conventional tissue biopsies. Illustrating this, in November 2023, Illumina Inc., a prominent American company specializing in sequencing and genomics, introduced TruSight Oncology 500 ctDNA v2. This research-oriented liquid biopsy panel is designed for the noninvasive genomic assessment of solid tumors and features an enhanced hybrid-capture panel coupled with DRAGEN bioinformatics, enabling the analysis of 523 biomarkers even with minimal cell-free DNA input. The assay adeptly enriches and identifies structural variants, copy number variations, insertions/deletions, and immuno-oncology parameters with impressive analytical precision, offers simplified laboratory processes through a single hybridization step with a turnaround time of less than four days, and is compatible with NovaSeq systems and future automated platforms. It proves beneficial when tissue is not available or its testing is delayed, serves as a valuable supplement to tissue-based testing, and supports extensive pan-cancer research and clinical trial screening by delivering prompt insights, demonstrating efficacy with low-input samples, and facilitating widespread implementation across various laboratory settings.

Liquid Biopsy Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Access The Complete Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Liquid Biopsy Market Regional Analysis And Leading Geography

North Americawas the largest region in the liquid biopsy market in 2025. Western Europewas the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Liquid Biopsy Market Size And Revenue Forecast Through 2030

The market for liquid biopsy has experienced a significant expansion recently, projected to increase from $1.46 billion in 2025 to $1.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.3%. This notable growth during the past period is largely due to the inherent drawbacks of conventional tissue biopsy methods, a

The liquid biopsy market is poised for significant expansion, projected to reach $3.11 billion by 2030, driven by a robust compound annual growth rate (CAGR) of 16.2%. This forthcoming expansion is fueled by several key factors, including the escalating demand for personalized cancer therapies, a greater integration of liquid biopsy into standard cancer detection protocols, its broadened utility in tracking cancer recurrence, augmented expenditure on cancer diagnostics, and heightened understanding and acceptance among both medical professionals and patients. Within this projected timeframe, notable market developments are anticipated, such as the increased embrace of non-surgical cancer diagnostic methods, a heightened focus on leveraging liquid biopsy for the earliest possible identification of cancer, the growing need for continuous monitoring of therapeutic effectiveness, its wider application in tailored cancer treatment strategies, and its growing endorsement as a viable substitute for traditional tissue biopsies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

Liquid Biopsy Market Growth Drivers: What Factors Are Accelerating Expansion?

Enhanced governmental financial support directed towards improving cancer detection capabilities stands as a principal factor propelling the expansion of the liquid biopsy sector. This heightened public investment in cancer detection advancements stems largely from the escalating worldwide prevalence of cancer, the critical necessity for early identification to optimize therapeutic results, and a concentrated effort to curb medical expenditures through the implementation of pioneering diagnostic methodologies. Such governmental backing facilitates the liquid biopsy market by expediting research and development initiatives, providing crucial support for clinical studies, and encouraging the uptake of sophisticated, minimally invasive diagnostic tools that aid in earlier cancer identification and the formulation of tailored treatment plans. A pertinent example is the £118 million (equivalent to $150.38) earmarked by UK Research and Innovation, as reported in October 2024 on the UK government’s official platform, gov.UK, where £54 million originated from governmental sources and an additional £64 million (or $81.55) was contributed by collaborating entities, underscoring the significant financial impetus provided for advancements in cancer diagnostics.

Liquid Biopsy Market Segment Performance And Strategic Opportunities

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

Liquid Biopsy Market Trends: What Is Shaping Future Industry Growth?

Key players in the liquid biopsy sector are prioritizing the creation of cutting-edge technologies, like extensive circulating tumor DNA (ctDNA) genomic-profiling assays, with the goal of expediting noninvasive cancer characterization, facilitating quicker medical treatment choices, and expanding the availability of precision oncology, particularly in situations where tissue is scarce or inaccessible. These comprehensive ctDNA genomic-profiling assays work by examining fragments of cell-free DNA originating from tumors present in the bloodstream, thereby identifying somatic small variants, alterations in copy number, insertions or deletions, and indicators relevant to immuno-oncology such as bTMB and bMSI. This approach provides a more extensive understanding of the tumor without the drawbacks of invasive procedures, potential sampling biases, and extended processing times associated with conventional tissue biopsies. Illustrating this, in November 2023, Illumina Inc., a prominent American company specializing in sequencing and genomics, introduced TruSight Oncology 500 ctDNA v2. This research-oriented liquid biopsy panel is designed for the noninvasive genomic assessment of solid tumors and features an enhanced hybrid-capture panel coupled with DRAGEN bioinformatics, enabling the analysis of 523 biomarkers even with minimal cell-free DNA input. The assay adeptly enriches and identifies structural variants, copy number variations, insertions/deletions, and immuno-oncology parameters with impressive analytical precision, offers simplified laboratory processes through a single hybridization step with a turnaround time of less than four days, and is compatible with NovaSeq systems and future automated platforms. It proves beneficial when tissue is not available or its testing is delayed, serves as a valuable supplement to tissue-based testing, and supports extensive pan-cancer research and clinical trial screening by delivering prompt insights, demonstrating efficacy with low-input samples, and facilitating widespread implementation across various laboratory settings.

Liquid Biopsy Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Access The Complete Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Liquid Biopsy Market Regional Analysis And Leading Geography

North Americawas the largest region in the liquid biopsy market in 2025. Western Europewas the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Liquid Biopsy Market Size And Revenue Forecast Through 2030

The market for liquid biopsy has experienced a significant expansion recently, projected to increase from $1.46 billion in 2025 to $1.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.3%. This notable growth during the past period is largely due to the inherent drawbacks of conventional tissue biopsy methods, a

The liquid biopsy market is poised for significant expansion, projected to reach $3.11 billion by 2030, driven by a robust compound annual growth rate (CAGR) of 16.2%. This forthcoming expansion is fueled by several key factors, including the escalating demand for personalized cancer therapies, a greater integration of liquid biopsy into standard cancer detection protocols, its broadened utility in tracking cancer recurrence, augmented expenditure on cancer diagnostics, and heightened understanding and acceptance among both medical professionals and patients. Within this projected timeframe, notable market developments are anticipated, such as the increased embrace of non-surgical cancer diagnostic methods, a heightened focus on leveraging liquid biopsy for the earliest possible identification of cancer, the growing need for continuous monitoring of therapeutic effectiveness, its wider application in tailored cancer treatment strategies, and its growing endorsement as a viable substitute for traditional tissue biopsies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

Liquid Biopsy Market Growth Drivers: What Factors Are Accelerating Expansion?

Enhanced governmental financial support directed towards improving cancer detection capabilities stands as a principal factor propelling the expansion of the liquid biopsy sector. This heightened public investment in cancer detection advancements stems largely from the escalating worldwide prevalence of cancer, the critical necessity for early identification to optimize therapeutic results, and a concentrated effort to curb medical expenditures through the implementation of pioneering diagnostic methodologies. Such governmental backing facilitates the liquid biopsy market by expediting research and development initiatives, providing crucial support for clinical studies, and encouraging the uptake of sophisticated, minimally invasive diagnostic tools that aid in earlier cancer identification and the formulation of tailored treatment plans. A pertinent example is the £118 million (equivalent to $150.38) earmarked by UK Research and Innovation, as reported in October 2024 on the UK government’s official platform, gov.UK, where £54 million originated from governmental sources and an additional £64 million (or $81.55) was contributed by collaborating entities, underscoring the significant financial impetus provided for advancements in cancer diagnostics.

Liquid Biopsy Market Segment Performance And Strategic Opportunities

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

Liquid Biopsy Market Trends: What Is Shaping Future Industry Growth?

Key players in the liquid biopsy sector are prioritizing the creation of cutting-edge technologies, like extensive circulating tumor DNA (ctDNA) genomic-profiling assays, with the goal of expediting noninvasive cancer characterization, facilitating quicker medical treatment choices, and expanding the availability of precision oncology, particularly in situations where tissue is scarce or inaccessible. These comprehensive ctDNA genomic-profiling assays work by examining fragments of cell-free DNA originating from tumors present in the bloodstream, thereby identifying somatic small variants, alterations in copy number, insertions or deletions, and indicators relevant to immuno-oncology such as bTMB and bMSI. This approach provides a more extensive understanding of the tumor without the drawbacks of invasive procedures, potential sampling biases, and extended processing times associated with conventional tissue biopsies. Illustrating this, in November 2023, Illumina Inc., a prominent American company specializing in sequencing and genomics, introduced TruSight Oncology 500 ctDNA v2. This research-oriented liquid biopsy panel is designed for the noninvasive genomic assessment of solid tumors and features an enhanced hybrid-capture panel coupled with DRAGEN bioinformatics, enabling the analysis of 523 biomarkers even with minimal cell-free DNA input. The assay adeptly enriches and identifies structural variants, copy number variations, insertions/deletions, and immuno-oncology parameters with impressive analytical precision, offers simplified laboratory processes through a single hybridization step with a turnaround time of less than four days, and is compatible with NovaSeq systems and future automated platforms. It proves beneficial when tissue is not available or its testing is delayed, serves as a valuable supplement to tissue-based testing, and supports extensive pan-cancer research and clinical trial screening by delivering prompt insights, demonstrating efficacy with low-input samples, and facilitating widespread implementation across various laboratory settings.

Liquid Biopsy Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Access The Complete Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Liquid Biopsy Market Regional Analysis And Leading Geography

North Americawas the largest region in the liquid biopsy market in 2025. Western Europewas the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Liquid Biopsy Market Through 2030?

The liquid biopsy market has experienced rapid expansion in recent years. This market is projected to expand from $1.46 billion in 2025 to $1.71 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.3%. The expansion observed during the historic period was driven by factors such as the drawbacks of conventional tissue biopsy methods, the rising global prevalence of cancer, the swift embrace of blood-based diagnostic tools, developments in molecular biology, and a heightened emphasis on detecting cancer early.

The liquid biopsy market size is projected for substantial expansion in the next few years. It is expected to reach $3.11 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.2%. This growth in the forecast period is attributable to increasing demand for precision oncology, wider adoption in routine cancer screening, expanding applications in recurrence monitoring, growth in oncology diagnostic spending, and increasing awareness among clinicians and patients. Major trends during this period include the rising acceptance of non-invasive cancer diagnostics, increased use of liquid biopsy for early cancer detection, a growing need for real-time treatment monitoring, the expansion of liquid biopsy in personalized oncology, and its increasing clinical acceptance as an alternative to tissue biopsy.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

Which Significant Factors Are Encouraging Growth In The Liquid Biopsy Market?

Increased government financial support for advancing cancer detection is a primary catalyst for the expansion of the liquid biopsy market. This governmental funding is largely a response to the escalating global prevalence of cancer, the critical demand for early diagnosis to improve treatment efficacy, and the emphasis on reducing healthcare expenses through innovative diagnostic methods. Such funding benefits liquid biopsy by expediting research and development efforts, providing assistance for clinical trials, and fostering the integration of sophisticated, non-invasive diagnostic technologies, ultimately leading to enhanced early cancer identification and customized treatment approaches. For example, in October 2024, gov.UK, a UK-based government website, reported that £118 ($150.38) million was designated for UK Research and Innovation, with £54 million originating from the government and £64 ($81.55) million contributed by partners. Therefore, the rise in government funding aimed at improving cancer detection is actively driving the growth of the liquid biopsy market.

How Is The Liquid Biopsy Market Examined Through Segment Analysis?

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

Which Trends Are Shaping The Liquid Biopsy Market Landscape?

Leading companies in the liquid biopsy market are focusing on developing innovative solutions, such as comprehensive circulating tumor DNA (ctDNA) genomic-profiling assays. These initiatives aim to accelerate noninvasive cancer profiling, facilitate faster therapeutic decision-making, and broaden access to precision oncology, particularly where tissue is limited or unobtainable. A ctDNA comprehensive genomic-profiling assay examines fragments of tumor-derived cell-free DNA found in blood to identify somatic small variants, copy-number changes, insertions/deletions, and immuno-oncology signatures (e.g., bTMB and bMSI), thereby offering more extensive tumor insight without the invasiveness, sampling bias, and longer turnaround time associated with traditional tissue biopsies. For example, in November 2023, Illumina Inc., a US-based sequencing and genomics company, launched TruSight Oncology 500 ctDNA v2. This research-use liquid biopsy panel for noninvasive genomic profiling of solid tumors integrates an expanded hybrid-capture panel with DRAGEN bioinformatics to sequence 523 biomarkers from low cfDNA input. The assay enriches and detects SVs, CNVs, indels, and immuno-oncology metrics with high analytical performance, provides streamlined workflows involving a single hybridization step and a less than 4-day turnaround, and is compatible with NovaSeq systems and upcoming automation. It supports usage when tissue is unavailable or delayed, complements tissue testing, and enables broad pan-cancer research and trial screening, offering faster insights, suitability for low-input samples, and easier adoption across distributed lab environments.

Who Are The Key Market Participants In The Liquid Biopsy Market?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Access The Complete Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

What Is The Largest Regional Market In The Liquid Biopsy Market?

North America was the largest region in the liquid biopsy market in 2025. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Liquid Biopsy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=2815&type=smp

Browse Through More Reports Similar to the Global Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Biopsy Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Liquid Biopsy Market From 2026 To 2030?

The liquid biopsy market has shown significant expansion in recent years. It is projected to grow from $1.46 billion in 2025 to $1.71 billion in 2026, with a compound annual growth rate (CAGR) of 17.3%. This historical development can be attributed to various factors, including the limitations inherent in traditional tissue biopsy methods, a rising global prevalence of cancer, the prompt adoption of blood-based diagnostics, advancements made in molecular biology techniques, and a heightened focus on the early detection of cancer.

The liquid biopsy market is projected for significant expansion over the coming years. Its value is estimated to reach $3.11 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.2%. This anticipated growth during the forecast period stems from factors such as heightened demand for precision oncology, wider incorporation into routine cancer screening, broader uses in recurrence monitoring, an increase in oncology diagnostic expenditures, and growing recognition among healthcare professionals and patients. Key trends shaping the forecast period encompass the increasing embrace of non-invasive cancer diagnostics, the expanded application of liquid biopsy for early cancer identification, a heightened need for real-time treatment oversight, the broadening role of liquid biopsy in personalized oncology, and its increasing clinical approval as a substitute for tissue biopsy.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

What Leading Drivers Are Supporting The Liquid Biopsy Market Expansion?

The expansion of the liquid biopsy market is significantly propelled by an increase in government funding dedicated to advancing cancer detection. This public investment in enhanced cancer detection methods primarily stems from the escalating worldwide prevalence of cancer, the necessity for early diagnosis to improve patient outcomes, and the focus on reducing healthcare expenditures through innovative diagnostic technologies. Government financial support benefits liquid biopsy by expediting research and development, backing clinical trials, and fostering the wider adoption of advanced, non-invasive diagnostic tools, thereby enhancing early cancer identification and personalized treatment strategies. For instance, in October 2024, gov.UK, a UK-based government website, announced that UK Research and Innovation received a total allocation of £118 ($150.38) million, comprising £54 million from the government and £64 ($81.55) million from partners. Consequently, the rising government funding for the progression of cancer detection is indeed fueling the growth of the liquid biopsy market.

How Are Segments Identified Within The Liquid Biopsy Market Segment Framework?

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

What Emerging Trends Are Seen In The Liquid Biopsy Market?

Companies operating in the liquid biopsy market are prioritizing the development of novel solutions, including comprehensive circulating tumor DNA (ctDNA) genomic-profiling assays. These initiatives aim to expedite noninvasive cancer profiling, enable more rapid therapeutic decision-making, and broaden access to precision oncology in situations where tissue is limited or cannot be obtained. Such an assay operates by analyzing tumor-derived cell-free DNA fragments found in blood, detecting somatic small variants, copy-number changes, insertions/deletions, and immuno-oncology signatures (e.g., bTMB and bMSI). This method provides broader tumor insight, bypassing the invasiveness, sampling bias, and longer turnaround time typical of conventional tissue biopsies. For example, in November 2023, Illumina Inc., a US-based sequencing and genomics company, unveiled TruSight Oncology 500 ctDNA v2. This research-use liquid biopsy panel is designed for noninvasive genomic profiling of solid tumors, featuring an expanded hybrid-capture panel integrated with DRAGEN bioinformatics for sequencing 523 biomarkers from low cfDNA input. This assay is capable of enriching and detecting SVs, CNVs, indels, and immuno-oncology metrics with high analytical performance. It provides streamlined workflows, including a single hybridization step and a turnaround time of less than 4 days, while being compatible with NovaSeq systems and upcoming automation. The solution supports applications when tissue is unavailable or delayed, complements tissue testing, and enables broad pan-cancer research and trial screening. It offers benefits such as faster insights, suitability for low-input samples, and easier adoption across distributed lab environments.

Who Are The Companies Competing Within The Liquid Biopsy Market?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Get The Full Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Which Region Represents The Largest Share Of The Liquid Biopsy Market?

North America was the largest region in the liquid biopsy market in 2025. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Liquid Biopsy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Browse Through More Reports Similar to the Global Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Biopsy Devices Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Cancer Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Liquid Biopsy Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The liquid biopsy market size has experienced rapid growth in recent years. It is projected to expand from $1.46 billion in 2025 to $1.71 billion in 2026, at a compound annual growth rate (CAGR) of 17.3%. The market’s historical growth can be attributed to several factors including the limitations inherent in traditional tissue biopsy procedures, the rising global incidence of cancer, the early adoption of blood-based diagnostic methods, progress in molecular biology techniques, and a heightened focus on early cancer diagnosis.

The liquid biopsy market size is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $3.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.2%. The projected increase throughout this period stems from several factors, including a heightened need for precision oncology, greater implementation in routine cancer screenings, broadening uses in recurrence tracking, increased expenditure on oncology diagnostics, and improved understanding among healthcare professionals and patients. Key developments expected during the forecast period encompass a surging embrace of non-invasive methods for cancer diagnosis, more frequent deployment of liquid biopsy for detecting cancer early, an escalating requirement for continuous treatment assessment, the expansion of liquid biopsy within personalized oncology, and a growing clinical acknowledgment as a substitute for tissue biopsy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

What Key Drivers Are Influencing The Growth Of The Liquid Biopsy Market?

Elevated government financial support for advancing cancer detection is a key driver in the growth of the liquid biopsy market. This funding is primarily attributed to the increasing worldwide burden of cancer, the imperative for early diagnosis to improve treatment outcomes, and the focus on reducing healthcare costs through innovative diagnostic technologies. Governmental investment aids liquid biopsy by expediting research and development, supporting clinical trials, and promoting the adoption of advanced, non-invasive diagnostic tools, thereby enhancing early cancer identification and personalized treatment strategies. For instance, in October 2024, gov.UK, a UK-based government website, announced an allocation of £118 ($150.38) million to UK Research and Innovation, comprising £54 million from the government and £64 ($81.55) million from partners. Consequently, the augmented government funding for improving cancer detection is propelling the expansion of the liquid biopsy market.

What Major Segment Divisions Exist Within The Liquid Biopsy Market?

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

What Key Developments And Trends Are Impacting The Liquid Biopsy Market?

Leading companies within the liquid biopsy market are concentrating on developing innovative solutions, such as comprehensive circulating tumor DNA (ctDNA) genomic-profiling assays. These advancements aim to accelerate noninvasive cancer profiling, facilitate quicker therapeutic decision-making, and broaden access to precision oncology, particularly where tissue samples are limited or unobtainable. A comprehensive ctDNA genomic-profiling assay functions by analyzing fragments of tumor-derived cell-free DNA in the bloodstream to identify somatic small variants, copy-number changes, insertions/deletions, and immuno-oncology signatures (e.g., bTMB and bMSI). This offers extensive tumor insight without the invasiveness, potential sampling bias, and extended turnaround times associated with traditional tissue biopsies. For example, in November 2023, Illumina Inc., a US-based sequencing and genomics company, launched TruSight Oncology 500 ctDNA v2, a research-use liquid biopsy panel designed for noninvasive genomic profiling of solid tumors. This panel integrates an expanded hybrid-capture panel with DRAGEN bioinformatics, enabling the sequencing of 523 biomarkers from low cfDNA input. The assay effectively enriches and detects SVs, CNVs, indels, and immuno-oncology metrics with high analytical performance, provides streamlined workflows involving a single hybridization step and a turnaround time of less than 4 days, and is compatible with NovaSeq systems and upcoming automation. It proves useful when tissue is unavailable or delayed, complements tissue testing, and supports broad pan-cancer research and trial screening, delivering faster insights, suitability for low-input samples, and easier adoption across distributed lab environments.

Which Companies Are Leading Innovation In The Liquid Biopsy Market?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Read the full liquid biopsy market report here:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Liquid Biopsy Market?

North America was the largest region in the liquid biopsy market in 2025. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Liquid Biopsy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2815&type=smp

Browse Through More Reports Similar to the Global Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Global Market Report

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Biopsy Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model